Advanced search
Publication Cover
Epigenomics Volume 5, 2013 - Issue 6
Submit an article Journal homepage
1,202
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Exploring and Exploiting the Aberrant DNA Methylation Profile of Endocrine-Resistant Breast Cancer

Andrew Stonea Cancer Epigenetics Program, Garvan Institute of Medical Research, Sydney, NSW, Australia. Tel.: +61 424 618 528 Fax: +61 293 555 [email protected]View further author information
,
Fatima Valdes-Morab Cancer Epigenetics Program, Garvan Institute of Medical Research, Sydney, NSW, Australia and St Vincent‘s Clinical School, Faculty of Medicine, UNSW, St Vincent‘s Hospital, Sydney, NSW, AustraliaView further author information
&
Susan J Clarkb Cancer Epigenetics Program, Garvan Institute of Medical Research, Sydney, NSW, Australia and St Vincent‘s Clinical School, Faculty of Medicine, UNSW, St Vincent‘s Hospital, Sydney, NSW, AustraliaView further author information
Pages 595-598 | Published online: 28 Nov 2013

References

  • Harvey JM , ClarkGM, OsborneCK, AllredDC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol.17(5) , 1474–1481 (1999).
  • Musgrove EA , SutherlandRL. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer9(9) , 631–643 (2009).
  • Jatoi I , AndersonWF, JeongJH, RedmondCK. Breast cancer adjuvant therapy: time to consider its time-dependent effects. J. Clin. Oncol.29(17) , 2301–2304 (2011).
  • Early Breast Cancer Trialists‘ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet365(9472) , 1687–1717 (2005).
  • Kennecke H , YerushalmiR, WoodsR et al. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol. 28(20) , 3271–3277 (2010).
  • Jones PA , BaylinSB. The epigenomics of cancer. Cell128(4) , 683–692 (2007).
  • Glasspool RM , TeodoridisJM, BrownR. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br. J. Cancer94(8) , 1087–1092 (2006).
  • Mulero-Navarro S , EstellerM. Epigenetic biomarkers for human cancer: the time is now. Crit. Rev. Oncol. Hematol.68(1) , 1–11 (2008).
  • How Kit A , NielsenHM, TostJ. DNA methylation based biomarkers: practical considerations and applications. Biochimie94(11) , 2314–2337 (2012).
  • Nogueira Da Costa A , HercegZ. Detection of cancer-specific epigenomic changes in biofluids: powerful tools in biomarker discovery and application. Mol. Oncol.6(6) , 704–715 (2012).
  • Jahr S , HentzeH, EnglischS et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61(4) , 1659–1665 (2001).
  • Van De Voorde L , SpeeckaertR, Van Gestel D et al. DNA methylation-based biomarkers in serum of patients with breast cancer. Mutat. Res.751(2) , 304–325 (2012).
  • Maier S , DahlstroemC, HaefligerC, PlumA, PiepenbrockC. Identifying DNA methylation biomarkers of cancer drug response. Am. J. Pharmacogenomics5(4) , 223–232 (2005).
  • Hegi ME , DiserensAC, GorliaT et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10) , 997–1003 (2005).
  • Agrelo R , ChengWH, SetienF et al. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc. Natl Acad. Sci. USA 103(23) , 8822–8827 (2006).
  • Veeck J , RoperoS, SetienF et al. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J. Clin. Oncol. 28(29) , e563–e564; author reply e565–e566 (2010).
  • Stone A , CowleyMJ, Valdes-MoraF et al. BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer. Mol. Cancer Ther. 12(9) , 1874–1885 (2013).
  • Linke SP , BremerTM, HeroldCD, SauterG, DiamondC. A multimarker model to predict outcome in tamoxifen-treated breast cancer patients. Clin. Cancer Res.12(4) , 1175–1183 (2006).
  • Babidge WJ , ButlerLM, BurtonMA, CowledPA. Methylation of CpG sites in exon 2 of the bcl-2 gene occurs in colorectal carcinoma. Anticancer Res.21(4A) , 2809–2814 (2001).
  • Dauksa A , GulbinasA, BarauskasG, PundziusJ, OldenburgJ, El-MaarriO. Whole blood DNA aberrant methylation in pancreatic adenocarcinoma shows association with the course of the disease: a pilot study. PLoS ONE7(5) , e37509 (2012).
  • Scher MB , ElbaumMB, MogilevkinY et al. Detecting DNA methylation of the BCL2, CDKN2A and NID2 genes in urine using a nested methylation specific polymerase chain reaction assay to predict bladder cancer. J. Urol. 188(6) , 2101–2107 (2012).
  • Stone A , Valdes-MoraF, GeeJM et al. Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer. PLoS ONE 7(7) , e40466 (2012).
  • Magnani L , StoeckA, ZhangX et al. Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc. Natl Acad. Sci. USA 110(16) , e1490 –e1499 (2013).
  • Bertelli G , ParidaensR. Optimal sequence of hormonotherapy in advanced breast cancer. Curr. Opin. Oncol.18(6) , 572 –577 (2006).
  • Fan M , YanPS, Hartman-FreyC et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res. 66(24) , 11954 –11966 (2006).
  • Hinshelwood RA , MelkiJR, HuschtschaLI et al. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning. Hum. Mol. Genet. 18(16) , 3098 –3109 (2009).
  • Gazzoli I , LodaM, GarberJ, SyngalS, KolodnerRD. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res.62(14) , 3925–3928 (2002).
  • Wong EM , SoutheyMC, FoxSB et al. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev. Res. 4(1) , 23 –33 (2011).
  • Dedeurwaerder S , DefranceM, CalonneE, DenisH, SotiriouC, FuksF. Evaluation of the Infinium methylation 450K technology. Epigenomics3(6) , 771 –784 (2011).
  • Bock C , TomazouEM, BrinkmanAB et al. Quantitative comparison of genome-wide DNA methylation mapping technologies. Nat. Biotech. 28(10) , 1106 –1114 (2010).
  • TCGA Network. Comprehensive molecular portraits of human breast tumours. Nature490(7418) , 61 –70 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.